Experienced in Thrombocytopenia

Dr. Elizabeth A. Griffiths

Hematology Oncology | Hematology | Oncology
Elm And Carlton St, 
Buffalo, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Thrombocytopenia
Elm And Carlton St, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Griffiths is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Griffiths is rated as an Experienced provider by MediFind in the treatment of Thrombocytopenia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 127 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Thrombocytopenia.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Elm And Carlton St, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Cedazuridine
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: BLU-263
Study Phase: Phase 2/Phase 3
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML
Enrollment Status: Completed
Publish Date: July 14, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Nivolumab, Poly ICLC
Study Phase: Phase 1
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Drug
Study Drugs: ASTX660, ASTX727
Study Phase: Phase 1
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy
Enrollment Status: Completed
Publish Date: June 06, 2023
Intervention Type: Biological
Study Drug: Trivalent Influenza Vaccine
Study Phase: Early Phase 1
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: June 16, 2021
Intervention Type: Drug
Study Drugs: Rigosertib, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients With AML Harboring Mutations in IDH2 Who Have Failed or Been Refractory to One Prior Line of Therapy
A Phase II Study of Intensive Salvage Therapy Followed by Enasidenib for Patients With AML Harboring Mutations in IDH2 Who Have Failed or Been Refractory to One Prior Line of Therapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

127 Total Publications

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 12, 2025
Similar Doctors
Advanced in Thrombocytopenia
Dr. Bhuvana G. Ramkumar
Hematology Oncology | Hematology | Oncology
Advanced in Thrombocytopenia
Dr. Bhuvana G. Ramkumar
Hematology Oncology | Hematology | Oncology

Niagara Falls Memorial Medical Center

621 10th St, Fl 4, 
Niagara Falls, NY 
 (15.2 miles away)
716-298-4869
Languages Spoken:
English
See accepted insurances

Bhuvana Ramkumar is a Hematologist Oncology specialist and a Hematologist in Niagara Falls, New York. Dr. Ramkumar is rated as an Advanced provider by MediFind in the treatment of Thrombocytopenia. Her top areas of expertise are Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), Childhood Iron Deficiency Anemia, and Childhood Acute Myeloid Leukemia.

Advanced in Thrombocytopenia
Dr. Jairus T. Ibabao
Hematology Oncology | Oncology | Hematology
Advanced in Thrombocytopenia
Dr. Jairus T. Ibabao
Hematology Oncology | Oncology | Hematology

Rpci Oncology, PC

21 Porter Ave, 
Jamestown, NY 
 (60.5 miles away)
716-664-1909
Languages Spoken:
English
See accepted insurances

Jairus Ibabao is a Hematologist Oncology specialist and an Oncologist in Jamestown, New York. Dr. Ibabao is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Paget Disease of the Breast, Pleuropulmonary Blastoma, Chronic Lymphocytic Leukemia (CLL), and Lung Cancer.

Advanced in Thrombocytopenia
Dr. Hasan A. Rizvi
Hematology Oncology | Hematology | Oncology
Advanced in Thrombocytopenia
Dr. Hasan A. Rizvi
Hematology Oncology | Hematology | Oncology

Olean General Hospital

515 Main St, 
Olean, NY 
 (61.5 miles away)
716-375-6993
Languages Spoken:
English
See accepted insurances

Hasan Rizvi is a Hematologist Oncology specialist and a Hematologist in Olean, New York. Dr. Rizvi is rated as an Advanced provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Griffiths's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 19 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile